Pharma BD Deal Intelligence

BeOne Medicines Ltd. / Huahui Health Ltd.

2026 · Licensing/Option · $2.0B · Complete

BeOne Medicines entered a global exclusive option, license and collaboration agreement with China-based Huahui Health for trispecific antibody HH160; $20M upfront, $100M option-exercise payment, and up to $1.9B in development/regulatory/commercial milestones, totaling ~$2.02B excluding royalties.

Key facts

• Announced Apr 30, 2026
• Closed Apr 30, 2026
• Deal value $2.0B
• Deal type Licensing/Option
• Therapeutic area Solid tumors (oncology immunotherapy)
• Indications Solid tumors (oncology immunotherapy)
• Key assets HH160 (PD-1 / CTLA-4 / VEGF-A trispecific antibody, preclinical)
• Mechanism Trispecific antibody simultaneously targeting PD-1, CTLA-4 and VEGF-A to combine checkpoint inhibition with anti-angiogenic activity in a single molecule

← Browse all deals  ·  How we score deals